Cyclooxygenase and prostanoids - Biological implications;Cyklooksygenaza i prostanoidy - znaczenie biologiczne

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 60, Issue , 2006, Pages 129-141

  Burdan, Franciszek ^a   Chałas, Anna ^b   Szumiło, Justyna ^c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Specjalistycznego Im Stefana Kardynała Wyszyńskiego SP ZOZ W Lublinie ^*  (Poland)

^c Katedra i Zak ad Patomorfologii Klinicznej   (Poland)

Author keywords

Arachidonic acid; COX inhibitors; COX 1; COX 2; COX 3; Cyclooxygenase; NSAID; Phospholipase; Prostacyclin; Prostaglandins; Thromboxane

Indexed keywords

PHOSPHOLIPASE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOXANE;

ANIMAL; DEGENERATIVE DISEASE; FEMALE; FETUS; FOREBRAIN; GENETICS; HUMAN; INFLAMMATION; KIDNEY; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PLACENTA; PREGNANCY; REVIEW; SPINAL CORD;

ANIMALS; CYCLOOXYGENASE INHIBITORS; ENGLISH ABSTRACT; FEMALE; FETUS; HUMANS; INFLAMMATION; KIDNEY; NEOPLASMS; NEURODEGENERATIVE DISEASES; PHOSPHOLIPASES; PLACENTA; PREGNANCY; PROSENCEPHALON; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; SPINAL CORD; THROMBOXANES;

EID: 33846284196     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Asano K., Lilly C.M., Drazen J.M.: Prostaglandin G/H synthase-2 is the constitutive and dominant isoform in cultured human lung epithelial cells. Am. J. Physiol., 1996; 271: L126-L131
2. Balsinde J., Winstead M.V., Dennis E.A.: Phospholipase A(2) regulation of arachidonic acid mobilization. FEBS Lett., 2002; 531: 2-6
3. Birney Y., Redmond E.M., Sitzmann J.V., Cahill P.A.: Eicosanoids in cirrhosis and portal. Prostaglandins Other Lipid Mediat., 2003; 72: 3-18
4. Boelsterli U.A.: Diclofenac-induced liver injury: A paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol., 2003; 192: 307-322
5. Botting R.: COX-1 and COX-3 inhibitors. Thromb. Res., 2003; 110: 269-272
6. Botting R., Ayoub S.S.: COX-3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins Leukot. Essent. Fatty Acids., 2005; 72: 85-87
7. Breder C.D., Dewitt D., Kraig R.P.: Characterization of inducible cyclooxygenase in rat brain. J. Comp. Neurol., 1995; 355: 296-315
8. Brown J.R., DuBois R.N.: Cyclooxygenase as a target in lung cancer. Clin. Cancer. Res., 2004; 10: 4266s-4269s
9. Browner M.F.: The structure of human cyclooxygenase-2 and selective inhibitors. W: Selective COX-2 inhibitors-pharmacology, clinical effects and therapeutic potential. Red.: Vane J., Botting J. Kluwer Academic Publishers., Dordrecht 1998, 19-26
10. Burdan F.: Comparison of developmental toxicity of selective and nonselective cyclooxygenase-2 inhibitors in CRL: (WI)WUBR Wistar rats-DFU and piroxicam study. Toxicology, 2005; 211: 12-25
11. Burdan F.: Developmental toxicity evaluation of ibuprofen and tolmetin administered in triple daily doses to Wistar CRL: (WI)WUBR rats. Birth Defects Res. Part B Dev. Reprod. Toxicol., 2004; 71: 321-330
12. Burdan F., Dudka J., Szumilo J., Korobowicz E., Klepacz L.: Prenatal effects of DuP-697-the irreversible, highly selective cyclooxygenase-2 inhibitor. Reprod. Toxicol., 2003; 17: 413-419
13. Burdan F., Korobowicz A.: Koksiby: wysoce selektywne inhibitory cyklooksygenazy-2 (Częs̈ć II)-działania niepoządane. Pol. Merkuriusz Lek., 2003; 14: 352-355
14. Burdan F., Szumilo J., Marzec B., Klepacz R., Dudka J.: Skeletal developmental effects of selective and nonselective cyclooxygenase-2 inhibitors administered through organogenesis and fetogenesis in Wistar CRL:(WI)WUBR rats. Toxicology, 2005; 216: 204-223
15. Cappon G.D., Cook J.C., Hurtt M.E:. Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res. B Dev. Reprod. Toxicol., 2003; 68: 47-56
16. Catella-Lawson F., Reilly M.P., Kapoor S.C., Cucchiara A.J., DeMarco S., Tournier B., Vyas S.N., FitzGerald G.A.: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med., 2001; 345: 1809-1817
17. Chakraborty I., Das S.K., Wang J., Dey S.K.: Developmental expression of the cyclo-oxygenase-1 and cyclo-oxygenase-2 genes in the periimplantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J. Mol. Endocrinol., 1996; 16: 107-122
18. Chandrasekharan N.V., Dai H., Roos K.L., Evanson N.K., Tomsik J., Elton T.S., Simmons D.L.: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression, Proc. Natl. Acad. Sci. USA, 2002; 99: 13926-13931
19. Cheng H.F., Harris R.C.: Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr. Pharm. Des., 2005; 11: 1795-1804
20. Cheng Y., Austin S.C., Rocca B., Koller B.H., Coffman T.M., Grosser T., Lawson J.A., FitzGerald G.A.: Role of prostacyclin in the cardiovascular responses to thromboxane A2. Science, 2002; 296: 539-541
21. Clark M.A., Convay T.M., Shorr R.G., Crooke S.T.: Identification and isolation of a mammalian protein which is antigenically and functionally related to the phospholipase A2 stimulatory peptide melittin. J. Biol. Chem., 1987; 262: 4402-4406
22. Cohn S.M., Schloemann S., Tessner T., Seibert K., Stenson W.F.: Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J. Clin. Invest., 1997; 99: 1367-1379
23. Cook J.C., Jacobson C.F., Gao F., Tassinari M.S., Hurtt M.E., DeSesso J.M.: Analysis of the nonsteroidal anti-inflammatory drug literature for potential developmental toxicity in rats and rabbits. Birth Defects Res. B Dev. Reprod. Toxicol., 2003; 68: 5-26
24. Crofford L.J., Wilder R.L., Ristimaki A.P, Sano H., Remmers E.F, Epps H.R., Hla T.: Cyclooxygenase-1 and-2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbal ester, and corticosteroids. J. Clin. Invest., 1994; 93: 1095-1101
25. Dachman R.: Increased risk of cardiovascular events with coxibs and NSAIDs. Lancet, 2005; 365: 1537-1538
26. Dannhardt G., Kiefer W.: Cyclooxygenase inhibitors-current status and future prospects. Eur. J. Med. Chem., 2001; 36: 109-126
27. Davies N.M., Good R.L., Roupe K.A., Yanez J.A.: Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error?-not as easy as 1,2,3. J. Pharm. Pharmaceut. Sci., 2004; 7: 217-226
28. Dogne J.M., Supuran C.T., Pratico D.: Adverse cardiovascular effects of the coxibs. J. Med. Chem., 2005; 48: 2251-2257
29. Espey L.L.: Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. Biol. Reprod., 1994; 50: 233-238
30. FitzGerald G.A.: Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am. J. Cardiol., 1991; 68: 11B-15B
31. Freissmuth M., Cassey P.J., Gilman A.G.: G proteins control diverse pathways of transmembrane signaling. FASEB J., 1989; 3: 2125-2131
32. Fritsche E., Baek S.J., King L.M., Zeldin D.C., Eling T.E., Bell D.A.: Functional characterization of cyclooxygenase-2 polymorphisms. J. Pharmacol. Exp. Ther., 2001; 299: 468-476
33. Fux R., Schwab M., Thon K.P., Gleiter C.H., Fritz P.: Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. Clin. Cancer. Res., 2005; 11: 4754-4760
34. Ganey P.E., Barton Y.W., Kinser S., Sneed R.A., Barton C.C., Roth R.A.: Involvement of cyclooxygenase-2 in the potentiation of allyl alcohol-induced liver injury by bacterial lipopolysaccharide. Toxicol. Appl. Pharmacol., 2001; 174: 113-121
35. Gijon M.A., Leslie C.C.: Phosholipases A2. Semin. Cell Dev. Biol., 1997; 8: 297-303
36. Gretzer B., Maricic N., Respondek M., Schuligoi R., Peskar B.M.: Effects of specific inhibition of cyclo-oxygenase-1 and cycol-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br. J. Pharmacol., 2001; 132: 1565-1573
37. Halushka M.K., Walker L.P., Halushka P.V.: Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin. Pharmacol. Ther., 2003; 73: 122-130
38. Hamberg M., Svensson J., Samuelsson B.: Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA, 1975; 72: 2294-2298
39. Harris R.C., McKanna J.A., Akai Y., Jacobson H.R., Dubois R.N., Breyer M.D.: Cyclooxygenase-2 is associated with the macula dense of rat kidney and increases with salt restriction. J. Clin. Invest., 1994; 94: 2504-2510
40. Hasturk S., Kemp B., Kalapurakal S.K., Kurie J.M., Hong W.K., Lee J.S.: Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer, 2002; 94: 1023-1031
41. Hatae T., Wada M., Yokoyama C., Shimonishi M., Tanabe T.: Prostacyclin-dependent apoptosis mediated by PRAR delta. J. Biol. Chem., 2001; 276: 46260-462567
42. Hull M.A.: Cyclooxygenase-2: how good is it as a target for cancer chemoprevention? Eur. J. Cancer, 2005; 41: 1854-1863
43. Humar B., Giovanoli O., Wolf A., Attenhofer M., Bendik I., Meier L., Muller H., Dobbie Z.: Germline alterations in the cyclooxygenase-2 gene are not associated with the development of extracolonic manifestations in a large swiss familial adenomatous polyposis kindred. Int. J. Cancer, 2000; 87: 812-817
44. Ito S., Carretero O.A., Abe K., Beierwaltes W.H., Yoshinaga K.: Effect of prostanoids on renin release from rabbit afferent arterioles with and without macula densa. Kidney Int., 1989; 35: 1138-1144
45. Jackson L.M., Wu K.C., Mahida Y.R., Jenkins D., Hawkey C.J.: Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut, 2000; 47: 762-770
46. Jakowicki J.A., Rechberger T. (red): Prostaglandyny we współczesnej ginekologii i połoznictwie. BiFolium, Lublin 1998
47. Kargman S., Charleson S., Cartwright M., Frank J., Riendeau D., Mancini J., Evans J., O'Neill G.: Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey and human gastrointestinal tracts. Gastroenterology, 1996; 111: 445-454
48. Khan K.N., Stanfield K.M., Dannenberg A., Seshan S.V., Baergen R.N., Baron D.A., Soslow R.A.: Cyclooxygenase-2 expression in the developing human kidney. Pediatr. Dev. Pathol., 2001; 4: 461-466
49. Khan K.N., Stanfield K.M., Harris R.K., Baron D.A.: Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Ren. Fail., 2001; 23: 321-330
50. Kiefer J.R., Pawlitz J.L., Moreland K.T., Stegeman R.A., Hood W.F., Gierse J.K., Stevens A.M., Goodwin D.C., Rowlinson S.W., Marnett L.J., Stallings W.C., Kurumbail R.G.: Structural insights into the stereochemistry of the cyclooxygenase reaction. Nature, 2000; 405: 97-101
51. Kömhoff M., Grone H.J., Klein T., Seyberth H.W., Nusing R.M.: Localization of cyclooxygenase-1 and-2 in adult and fetal human kidney: implication for renal function. Am. J. Physiol., 1997; 272: F460-F468
52. Kosaka T., Miyata A., Ihara H., Hara S., SugimotoT., Takeda O., Takahashi E., Tanabe T.: Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur. J. Biochem., 1994; 221: 889-897
53. Kujubu D.A., Herschman H.R.: Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J. Biol. Chem., 1992; 267: 7991-7994
54. Langenbach R., Morham S.G., Tiano H.F., Loftin C.D., Ghanayem B.I., Chulada P.C., Mahler J.F., Lee C.A., Goulding E.H., Kluckman K.D., Kim H.S., Smithies O.: Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell, 1995; 83: 483-492
55. LaValle J.B.: The COX-2 connection natural breakthrough treatment for arthritis, Alzheimer's and Cancer. Healing Arts Press, Rochester 2001
56. Lazarus M., Eguchi N., Matsumoto S., Nagata N., Yano T., Killian G.J., Urade Y.: Species-specific expression of microsomal prostaglandin E synthase-1 and cyclooxygenases in male monkey reproductive organs. Prostaglandins Leukot. Essent. Fatty Acids, 2004; 71: 233-240
57. Lecomte M., Laneuville O., Ji C., DeWitt D.L., Smith W.L.: Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J. Biol. Chem., 1994; 269: 13207-13215
58. Lichtenstein D.R., Wolfe M.M.: COX-2-Selective NSAIDs: new and improved? JAMA, 2000; 284: 1297-1299
59. Liscovitch M., Chalifa V., Pertile P., Chen C.S., Cantley L.C.: Novel function of phosphatidylinositol 4,5-bisphosphate as a cofactor for brain membrane phospholipase D. J. Biol. Chem., 1994; 269: 21403-21406
60. Malkowski M.G., Ginell S.L., Smith W.L., Garavito R.M.: The productive conformation of arachidonic acid bound to prostaglandin synthase. Science, 2000; 289: 1933-1937
61. Malkowski M.G., Thuresson E.D., Lakkides K.M., Rieke C.J., Micielli R, Smith W.L., Garavito R.M.: Structure of eicosapentaenoic and linoleic acids in the cyclooxygenase site of prostaglandyn endoperoxide H synthase-1. J. Biol. Chem., 2001; 276: 37547-37555
62. Mancini J.A., O'Neill G.P., Bayly C., Vickers P.J.: Mutation of serine-516 in human prostaglandin G/H synthase-2 to methionine or aspirin acetylation of this residue stimulates 15-R-HETE synthesis. FEBS Lett., 1994; 342: 33-37
63. McKanna J.A., Zhang M.Z., Wang J.L., Cheng H., Harris R.C.: Constitutive expression of cyclooxygenase-2 in rat vas deferens. Am. J. Physiol., 1998; 275: R227-R233
64. McLaughlin J.N., Shen L., Holinstat M., Brooks J.D., Dibenedetto E., Hamm H.E.: Functional selectivity of G protein signaling by agonist peptides and thrombin for the protease-activated receptor-1. J. Biol. Chem., 2005; 280: 25048-25059
65. Mejza F., Nizankowska E.: Selektywne inhibitory cyklooksygenazy 2 (COX-2). Post. Hig. Med. Dos̈w., 2001; 55: 287-302
66. Miller S.G., Kennedy M.B.: Regulation of brain type II Ca2+/calmodulin-dependent protein kinase by autophosphorylation: A Ca2+-triggered molecular switch. Cell, 1986; 44: 861-870
67. Niiro H., Otsuka T., Izuhara K., Yamaoka K., Ohshima K., Tanabe T., Hara S., Nemoto Y., Tanaka Y., Nakashima H., Niho Y.: Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils. Blood, 1997; 89: 1621-1628
68. O'Neill G.P., Ford-Hutchinson A.W.: Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett., 1993; 330: 156-160
69. Ostensen M.E., Skomsvoll J.F.: Anti-inflammatory pharmacotherapy during pregnancy. Expert Opin. Pharmacother., 2004; 5: 571-580
70. Sacerdoti D., Gatta A., McGiff J.C.: Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology. Prostaglandins Other Lipid Mediat., 2003; 72: 51-71
71. Sadurska B., Szumilo M.: Fosfolipazy A w komórkach ssaków-budowa, włas̈ciwos̈ci, rola fizjologiczna i patologiczna. Post. Hig. Med. Dos̈w., 2005; 59: 116-123
72. Salhab A.S., Gharaibeh M.N., Shomaf M.S., Amro B.I.: Meloxicam inhibits rabbit ovulation. Contraception, 2001; 63: 329-333
73. Sangha R.K., Walton J.C., Ensor. C.M., Tai H.H., Challis J.R.: Immunohistochemical localization, messenger ribonucleic acid abundance, and activity of 15-hydroxyprostaglandin dehydrogenase in placenta and fetal membranes during term and preterm labor. J. Clin. Endocrinol. Metab., 1994; 78: 982-989
74. Sawdy R.J., Slater D.M., Dennes W.J., Sullivan M.H., Bennett P.R.: The roles of the cyclo-oxygenases types one and two in prostaglandin synthesis in human fetal membranes at term. Placenta, 2000; 21: 54-57
75. Schonbeck U., Sukhova G.K., Graber P., Coulter S., Libby P.: Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol., 1999; 155: 1281-1291
76. Schror K., Smith E.F.: Dictionary of prostaglandins and related compounds. Medikon Verlag, Munchen 1990
77. Schwab J.M., Beiter T., Linder J.U., Laufer S., Schulz J.E., Meyermann R., Schluesener H.J.: COX-3 a virtual pain target in humans? FASEB J., 2003; 17: 2174-2175
78. Schwab J.M., Schluesener H.J., Laufer S.: COX-3: just another COX or solitary elusive target of paracetamol? Lancet, 2003; 361: 981-982
79. Schwab J.M., Schluesener H.J., Meyermann R., Serhan C.N.: COX-3 the enzyme and the concept: steps towards highly specialized pathways and precision therapeutics? Prostaglandins Leukot. Essent. Fatty Acids, 2003; 69: 339-343
80. Serhan C.N.: Lipoxin synthesis and its impact in inflammatory and vascular events. Biochim. Biophys. Acta, 1994; 1212: 1-25
81. Simmons D.L.: Variants of cyclooxygenase-1 and their roles in medicine. Thromb. Res., 2003; 110: 265-268
82. Sirois J.: Inducation of prostaglandin endoperoxide synthase-2 by human chorionic gonadotropin in bovine preovulatory follicles in vivo. Endocrinology, 1994; 135: 841-848
83. Slater D., Berger L., Newton R., Moore G., Bennett P.: The relative abundance of type 1 to type 2 cyclo-oxygenase mRNA in human amnion at term. Biochem. Biophys. Res. Commun., 1994; 198: 304-308
84. Slater D., Dennes W., Sawdy R., Allport V., Bennett P.: Expression of cycol-oxygenase types-1 and-2 in human fetal membranes throughout pregnancy. J. Mol. Endocrinol., 1999; 22: 125-130
85. Smith W.L., Bell T.G.: Immunohistochemical localization of prostaglandyn-forming cyclooxygenase in renal cortex. Am. J. Physiol., 1978; 235: F451-F457
86. Spirio L.N., Dixon D.A., Robertson J., Robertson M., Barrows J., Traer E., Burt R.W., Leppert M.F., White R., Prescott S.M.: The inducible prostaglandin biosynthetic enzyme, cyclooxygenase 2, is not mutated in patients with attenuated adenomatous polyposis coli. Cancer Res., 1998; 58: 4909-4912
87. Stajszczyk M., Gminski J.: Lipoksyny-nowe pochodne kwasu arachidonowego. Post. Hig. Med. Dos̈w., 1993; 47: 137-147
88. Stanfield K.M., Bell R.R., Lisowski A.R., English M.L, Saldeen S.S., Khan K.N.: Expression of cyclooxygenase-2 in embryonic and fetal tissues during organogenesis and late pregnancy. Birth Defects Res. Part A Clin. Mol. Teratol., 2003; 67: 54-58
89. Streck R.D., Kumpf S.W., Ozolins T.R., Stedman D.B.: Rat embryos express transcripts for cyclooxygenase-1 and carbonic anhydrase-4, but not for cyclooxygenase-2, during organogenesis. Birth Defects Res. Part B Dev. Reprod. Toxicol., 2003; 68: 57-69
90. Svensson C.I., Yaksh T.L.: The spinal phospholipase-cyclooxygenaseprostanoid cascade in nociceptive processing. Annu. Rev. Pharmacol. Toxicol., 2002; 42: 553-583
91. Tegeder I., Pfeilschifter J., Geisslinger G.: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J., 2001; 15: 2057-2072
92. Thuresson E.D., Malkowski M.G., Lakkides K.M., Rieke C.J., Mulichak A.M., Ginell S.L., Garavito R.M., Smith W.L.: Mutational and X-ray crystallographic analysis of the interaction of dihomo-gamma-linolenic acid with prostaglandin endoperoxide H synthases. J. Biol. Chem., 2001; 276: 10358-10365
93. Tillet J., Kostich L.M., VandeVusse L.: Use of over-The-counter medications during pregnency. J. Perinat. Neonatal Nurs., 2003; 17: 3-18
94. To K.F., Chan F.K., Cheng A.S., Lee T.L., Ng Y.P., Sung J.J.: Up-regulation of cyclooxygenase-1 and-2 in human gastric ulcer. Aliment. Pharmacol. Ther., 2001; 15: 25-34
95. Topper J.N., Cai J., Falb D., Gimbrone M.A. Jr: Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl. Acad. Sci. USA, 1996; 93: 10417-10422
96. Ulrich C.M., Bigler J., Sibert J., Greene E.A., Sparks R., Carlson C.S., Potter J.D.: Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum. Mutat., 2002; 20: 409-410
97. Ulrich C.M., Bigler J., Sparks R., Whitton J., Sibert J.G., Goode E.L., Yasui Y., Potter J.D.: Polymorphisms in PTGS1 (=COX-1) and risk of colorectal polyps. Cancer Epidemiol. Biomarkers Prev., 2004; 13: 889-893
98. Van Voorhis B.J., Huettner P.C., Clark M.R., Hill J.A.: Immunohistochemical localization of prostaglandin H synthase in the female reproductive tract and endometriosis. Am. J. Obstet. Gynaecol., 1990; 163: 57-62
99. Vane J.R., Botting R.M.: Selective COX-2 inhibitors. Pharmacology, clinical effects and therapeutic potential. Kluwer Academic Publishers, Dordrecht 1998
100. Walenga R.W., Kester M., Coroneos E., Butcher S., Dwivedi R., Statt C.: Constitutive expression of prostaglandin endoperoxide G/H synthetase (PGHS)-2 but not PGHS-1 in human tracheal epithelial cells in vitro. Prostaglandins, 1996; 52: 341-359
101. Walker L.A., Whorton A.R., Smigel M., France R., Frolich J.C.: Antidiuretic hormone increases renal prostaglandin synthesis in vivo. Am. J. Physiol., 1978; 235: F180-F185
102. Wallace J.L., de Lima O.M. Jr, Fiorucci S.: Lipoxins in gastric mucosal health and disease. Prostaglandins Leukot. Essent. Fatty Acids, 2005; 73: 251-255
103. Wallace J.L., McKnight W., Reuter B.K., Vergnolle N.: NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology, 2000; 119: 706-714
104. Warner T.D., Mitchell J.A.: Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J., 2004; 18: 790-804
105. Willoughby D.A., Moore A.R., Colville-Nash P.R.: COX-1, COX-2 and COX-3 and the future treatment of chronic inflammatory disease. Lancet, 2000; 355: 646-648
106. Wolf M.J., Izumi Y., Zorumski C.F., Gross R.W.: Long-term potentiation requires activation of calcium-independent phospholipase A2. FEBS Lett., 1995; 377: 358-362
107. Wong S.C.Y., Fukuchi M., Melnyk P., Rodger I.W., Giaid A.: Induction of cyclooxygenase-2 and activation of nuclear factor-kB in myocardium of patients with congestive heart failure. Circulation, 1998; 98: 100-103
108. Woszczek G., Pawliczak R., Kowalski M.L.: Leukotrieny-mediatory zapalenia. Post. Hig. Med. Dos̈w., 2003; 57: 593-610
109. Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A., Worley P.F.: Expression of a mitogen-inducible cyclooxygenase in brain neurons; regulation by synaptic activity and glucocorticoids. Neuron, 1993; 11: 371-386
110. Yamamoto Y., Yin M.J., Lin K.M., Gaynor R.B.: Sulindac inhibits activations of the NF-kB pathway. J. Biol. Chem., 1999; 274: 27307-27314
111. Zhang M.Z., Wang J.L., Cheng H.F., Harris R.C., McKanna J.A.: Cyclooxygenase-2 in rat nephron development. Am. J. Physiol., 1997; 273: F994-F1002